The efficacy and safety of deoxyribonucleotide natrium in the treatment of secondary pulmonary tuberculosis
10.3969/j.issn.1005-1678.2017.04.088
- VernacularTitle:3HRES/3HRE联合脱氧核苷酸钠治疗初治继发性肺结核临床疗效及安全性
- Author:
Fuan YU
;
Yongli QIAO
;
Chengjie ZHAO
- Keywords:
sodium deoxyribonucleotide;
pulmonary tuberculosis;
clinical research;
safety
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(4):266-267,270
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of deoxyribonucleotide natrium in the treatment of secondary pulmonary tuberculosis.Methods A total of 94 cases with secondary pulmonary tuberculosis included in this study were dividing into control group and experiment group with each 47 cases.The patients in the both groups were give regular treatment.Patients in the control group were given standard chemotherapy regimen 3HRES/3HRE and patients in the experiment group revieved sodium deoxyribonucleotide injection 150mL+5％injection of liquid glucose 250mL by intravenous drip with once a day.1 time/d,two groups of patients with a cycle of 28d,a total of one cycles of treatment.The clinical efficacy,CA125,CA199,function of liver and kidney,occurrence of adverse reactions were compared between the two groups.Results The clinical efficacy in experiment group was 94.44％,which significant higher than that in control group 75.00％(P<0.05).The serum level of CA125 and CA199 decreased after treatment with experiment group much lower than the control group(P<0.05).Compared with the control group,the ALT,AST,Cr and serum BUN levels before and after treatment,the difference was not statistically significant.The adverse drug reactions was not statistically different between the two groups.Conclusion Deoxyribonucleotide natrium in the treatment of secondary pulmonary tuberculosis was effective with high safety.
